Clinical trial

A Single-arm Open-label Safety Study of SMOFlipid to Evaluate the Risk of Developing Essential Fatty Acid Deficiency (EFAD) and/or Parenteral Nutrition-associated Cholestasis (PNAC) in Pediatric Patients 1 Month to 17 Years of Age and in Adult Patients, Who Are Anticipated to Need 8 Weeks or Longer of Parenteral Nutrition Treatment

ID

Name

SMOF-044-CP4 (PMR 4240-1)

Description

Evaluate the risk of developing EFAD and/or PNAC in adult and pediatric patients 1 month of age and older, who are anticipated to need 8 weeks or longer of parenteral nutrition treatment with SMOFlipid.

Trial arms

Trial start

2024-05-01

Estimated PCD

2026-03-01

Trial end

2026-09-01

Status

Not yet recruiting

Phase

Early phase I

Treatment

SMOFlipid® (lipid injectable emulsion)

SMOFlipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of SMOFlipid is 0.20 g/mL, and comprises a mixture of soybean oil, MCT, olive oil, and fish oil. SMOFlipid belongs to the pharmacotherapeutic group: "Solutions for parenteral nutrition, fat emulsions" (ATC-code: B05BA02). SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Arms:

Single arm SMOFlipid® (lipid injectable emulsion)

Size

100

Primary endpoint

Incidence of PNAC

Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days).

Time to direct bilirubin > 2mg/dL

Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days).

Incidence of EFAD

Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days).

Incidence of clinical EFAD

Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days).

Fatty acids

Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days).

Eligibility criteria

Age Limits: and Adults Inclusion Criteria: 1. Male or female patients, at least 1 month of age. 2. Patients who require PN for at least 5 days/week. 3. Patients who receive 80% or more of their total energy requirements as PN at enrollment and who are expected to receive 80% or more of their total energy requirements as PN for at least 56 days. 4. Written informed consent. In case of pediatric patients, informed consent must be obtained from parent(s) or legal representatives. If possible, the assent of the pediatric patient must also be obtained (according to local law). Exclusion Criteria: 1. Use of any other lipid injectable emulsion than SMOFlipid within 6 months prior to study participation 2. Known hypersensitivity to fish, egg, soybean, or peanut proteins, or to any of the active ingredients or excipients of SMOFlipid. 3. Hyperlipidemia or disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentration \>250 mg/dL in infants or \>400 mg/dL in older pediatric and adult patients). 4. Inborn errors of amino acid metabolism. 5. Cardiopulmonary instability (including pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support). 6. Hemophagocytic syndrome. 7. Liver enzymes (either AST, or ALT, or GGT) exceeding 2 x upper limit of normal range 8. Direct bilirubin exceeding 2 x upper limit of normal range 9. INR exceeding 2 x upper limit of normal range and patient not receiving oral anticoagulants. 10. Any known hepatic condition outside of IFALD that will increase direct bilirubin ≥2.0 mg/dL. 11. Clinically significant abnormal levels of any serum electrolyte (sodium, potassium, magnesium, calcium, chloride, phosphate). 12. Active bloodstream infection demonstrated by positive blood culture at screening. 13. Severe renal failure (eGFR \<15 ml/min per 1.73 m2) including patients on renal replacement therapy. 14. Abnormal blood pH, oxygen saturation, or carbon dioxide. 15. Pregnancy or lactation. 16. Participation in another interventional clinical study. 17. Unlikely to survive longer than 56 days.

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}

Updated at

2024-02-20

1 organization

Organization